Results 151 to 160 of about 53,515 (238)

Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis. [PDF]

open access: yesCancer Med
Tasaki Y   +19 more
europepmc   +1 more source

Intratumoral CTLA‐4 Blockade: Decoupling Local Immune Remodeling From Systemic Toxicity

open access: yes
MedComm – Oncology, Volume 5, Issue 4, December 2026.
Luyan Chen   +4 more
wiley   +1 more source

A Case of Recurrent Gastric Cancer in Which Rheumatoid Arthritis and Sjögren's Syndrome Became Evident With Nivolumab

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT A 59‐year‐old man with recurrent gastric cancer began nivolumab as third‐line therapy and subsequently experienced joint pain and dry eyes. Symptoms worsened despite NSAIDs. He was diagnosed with rheumatoid arthritis and Sjögren's syndrome, associated with nivolumab, and was successfully treated with immunosuppressive and anti‐rheumatic ...
Haruhiko Takemoto   +7 more
wiley   +1 more source

Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Introduction Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common.
Neharika Bandaru   +2 more
wiley   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

open access: yesInternational Journal of Cancer, Volume 159, Issue 9, Page 2262-2277, 1 November 2026.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong   +4 more
wiley   +1 more source

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. [PDF]

open access: yesInt J Clin Oncol
Nishio M   +14 more
europepmc   +1 more source

The Effect of Ipilimumab on the Endocrine Function

open access: yes, 2016
Class of 2016 AbstractObjectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma. Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least ...
Qyra, Ollga, McBride, Ali
core  

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

open access: yesInternational Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel   +26 more
wiley   +1 more source

Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial. [PDF]

open access: yesNat Commun
Ruffin AT   +26 more
europepmc   +1 more source

Curative‐Intent Pancreatectomy for Pancreatic Metastasis From Renal Cell Carcinoma 30 Years After Nephrectomy Following Lenvatinib Plus Pembrolizumab Therapy: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Renal cell carcinoma (RCC) is the most common primary site of pancreatic metastases, and complete resection confers a favorable prognosis. Lenvatinib plus pembrolizumab (LEN + PEM) is standard first‐line therapy for advanced RCC; however, induction therapy before resection of pancreatic metastasis has not been reported.
Yuta Kaneko   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy